君实生物全资子公司特瑞普利单抗获英国上市批准
财中社11月17日电君实生物（688180/01877）发布自愿披露公告，宣布其全资子公司TopAlliance Biosciences Inc.的特瑞普利单抗（英国商品名：LOQTORZI®）已获得英国药品和保健品管理局（MHRA）批准上市。该药物用于治疗两项适应症，包括联合顺铂和吉西他滨用于复发、不能手术或放疗的转移性鼻咽癌患者的一线治疗，以及联合顺铂和紫杉醇用于不可切除的晚期/复发性食管鳞癌患者的一线治疗。特瑞普利单抗成为英国首个且唯一用于鼻咽癌治疗的药物。
此次获批基于JUPITER-02和JUPITER-06两项重要临床研究的结果，前者显示特瑞普利单抗联合化疗使患者的疾病进展风险降低48%，死亡风险降低37%；而后者则表明其可显著延长晚期食管鳞癌患者的中位生存期6个月，达到17个月。该药物的上市将有助于公司在海外市场的拓展，提升国际影响力，并对公司的长期经营业绩产生积极影响。
2024年前三季度，君实生物-U实现收入12.71亿元，归母净利润-9.27亿元。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10